| Literature DB >> 25537673 |
Uday C Ghoshal1, Kok-Ann Gwee2, Minhu Chen3, Xiao R Gong2, Nitesh Pratap4, Xiaohua Hou5, Ari F Syam6, Murdani Abdullah6, Young-Tae Bak7, Myung-Gyu Choi8, Sutep Gonlachanvit9, Andrew S B Chua10, Kuck-Meng Chong11, Kewin T H Siah12, Ching-Liang Lu1, Lishou Xiong3, William E Whitehead1.
Abstract
BACKGROUND/AIMS: The development-processes by regional socio-cultural adaptation of an Enhanced Asian Rome III questionnaire (EAR3Q), a cultural adaptation of the Rome III diagnostic questionnaire (R3DQ), and its translation-validation in Asian languages are presented. As English is not the first language for most Asians, translation-validation of EAR3Q is essential. Hence, we aimed to culturally adapt the R3DQ to develop EAR3Q and linguistically validate it to show that the EAR3Q is able to allocate diagnosis according to Rome III criteria.Entities:
Keywords: Asia; Gastrointestinal diseases; Rome III criteria; Translations; Validation
Year: 2015 PMID: 25537673 PMCID: PMC4288097 DOI: 10.5056/jnm14045
Source DB: PubMed Journal: J Neurogastroenterol Motil ISSN: 2093-0879 Impact factor: 4.924
Figure.Outline of the process of development of Enhanced Asian Rome III questionnaire (EAR3Q) from Rome III diagnostic questionnaire (R3DQ) and its translation and validation in different Asian languages.
Number of Healthy Subjects, Patients With Irritable Bowel Syndrome, Functional Dyspepsia, and Functional Constipation Included in Validation Study and Their Demographic Parameters
| Demographic parameters | Healthy subjects | Irritable bowel syndrome | Functional constipation | Functional dyspepsia |
|---|---|---|---|---|
| Hindi validation study | n = 10 | n = 10 | n = 10 | n = 10 |
| Age (median [range], yr) | 26 (21–56) | 33 (17–53) | 45.5 (18–66) | 49.5 (26–65) |
| Gender (M:F) | 4:6 | 8:2 | 3:7 | 7:3 |
| Telegu validation study | n = 10 | n = 11 | n = 6 | n = 8 |
| Age (median [range], yr) | 25.5 (23–30) | 33.0 (18–62) | 42 (24–55) | 45.5 (24–63) |
| Gender (M:F) | 4:6 | 11:0 | 5:1 | 3:5 |
| Chinese validation study | n = 6 | n = 9 | n = 14 | n = 9 |
| Age (median [range], yr) | 26.5(24–47) | 46(24–65) | 41(20–59) | 42(23–65) |
| Gender (M:F) | 2:4 | 3:6 | 8:6 | 4:5 |
| Korean validation study | n = 14 | n = 9 | n = 11 | n = 6 |
| Age (median [range], yr) | 36.5 (24–52) | 37 (27–48) | 33 (31–65) | 38 (21–58) |
| Gender (M:F) | 5:9 | 6:3 | 4:7 | 0:6 |
| Indonesian validation study | n = 10 | n = 10 | n = 10 | n = 10 |
| Age (median [range], yr) | 32.8 (21–62) | 46.9 (22–72) | 43.1 (26–63) | 45.2 (22–67) |
| Gender (M:F) | 5:5 | 7:3 | 1:9 | 1:9 |
| Thai validation study | n = 10 | n = 10 | n = 10 | n = 10 |
| Age (median [range], yr) | 44 (26–66) | 45 (24–63) | 46.5 (37–65) | 53 (14–62) |
| Gender (M:F) | 3:7 | 2:8 | 3:7 | 1:9 |
| Total number of subjects | 60 | 59 | 61 | 53 |
Diagnostic Performance of Translated Versions of Enhanced Asian Rome III Questionnaires
| Clinical diagnostic category | Concordance between clinical and questionnaire-based diagnosis on initial visit | Sensitivity | Specificity | Concordance of the questionnaire between initial and 14th day visit | Kappa (EAR3Q-based diagnoses at initial and 2-week follow-up) | |
|---|---|---|---|---|---|---|
| Hindi | HS (n = 10) | 10 | 100% | 100% | 10 | 1.000 |
| IBS (n = 10) | 10 | 100% | 10 | 1.000 | ||
| 7 (70%) had FD symptoms also | 7 (70%) had FD symptoms also | |||||
| FC (n = 10) | 10 | 100% | 10 | 1.000 | ||
| 9 (90%) had FD symptoms also | 9 (90%) had FD symptoms also | |||||
| FD (n = 10) | 10 | 100% | 10 | 1.000 | ||
| 6 (60%) had IBS symptoms also | 4 (40%) had IBS symptoms also | |||||
| Telugu | HS (n = 10) | 10 | 100% | 100% | 10 | 1.000 |
| IBS (n = 11) | 11 | 100% | 11 | 1.000 | ||
| 3 (27%) had FD symptoms also | 2 (18%) had FD symptoms also | |||||
| FC (n = 6) | 6 | 100% | 6 | 1.000 | ||
| 1 (17%) had FD symptoms also | 1 (17%) had FD symptoms also | |||||
| FD (n = 8) | 8 | 100% | 8 | 1.000 | ||
| Chinese | HS (n = 6) | 6 | 100% | 100% | 6 | 1.000 |
| IBS (n = 9) | 9 | 100% | 7 (77.8%) | 0.700 | ||
| FC (n = 9) | 9 | 100% | 8 | 0.900 | ||
| 1 (11%) had FD symptoms also | ||||||
| FD (n = 14) | 14 | 100% | 10 | 0.700 | ||
| 5 (35.7%) had FC symptoms also | 2 (20%) had FC symptoms also | |||||
| 1 (10%) had IBS symptoms also | ||||||
| Korean | HS (n = 14) | 13 (93%) | 93% | 93% | 14 | 1.000 |
| IBS (n = 9) | 5 | 55.5% | 4 | 0.400 | ||
| 1 (11%) had FD and 1 (11%) had functional bloating also and 4 did not fulfil criteria for any specific FGIDs | 1 had FD and 4 did not fulfil criteria for any specific FGIDs | |||||
| FC (n = 6) | 4 | 67% | 3 | 0.500 | ||
| 2 (33%) had functional bloating also, 1 IBS and 1 did not fulfil criteria for any specific FGIDs | 1 (17%) had FD also and 3 had IBS | |||||
| FD (n = 11) | 3 | 27% | 3 | 0.300 | ||
| 3 (27%) had IBS also, 2 functional bloating, 1 IBS only and 5 did not fulfil criteria for any specific FGIDs | 3 (27%) had IBS also and 2 had functional bloating, 2 had IBS, and 4 did not fulfil criteria for any specific FGIDs | |||||
| Indonesian | HS (n = 10) | 9 | 90% | 90% | 9 | 0.900 |
| IBS (n = 10) | 6 | 60% | 3 | 0.300 | ||
| 3 had FD symptoms also | 2 had FD symptoms also | |||||
| FC (n = 10) | 3 | 30% | 1 | 0.100 | ||
| 2 had FD symptoms also | ||||||
| FD (n = 10) | 4 | 40% | 4 | 0.400 | ||
| 3 had IBS symptoms also | 1 had IBS | |||||
| Thai | HS (n = 10) | 9 | 90% | 90% | 8 | 0.800 |
| IBS (n = 10) | 6 | 60% | 8 | 0.800 | ||
| FC (n = 10) | 6 | 60% | 8 | 0.800 | ||
| 1 had IBS and 1 FD had symptoms also | ||||||
| FD (n = 10) | 8 | 80% | 8 | 0.800 | ||
| 1 (10%) had functional bloating also | 1 (10%) had functional bloating also | |||||
EAR3Q, Enhanced Asian Rome III questionnaires; HS, healthy subject; IBS, irritable bowel syndrome; FC, functional constipation; FD, functional dyspepsia.